Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT05885360 Active, not recruiting - Parkinson Disease Clinical Trials

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Start date: January 20, 2023
Phase: Phase 4
Study type: Interventional

This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.

NCT ID: NCT05866120 Active, not recruiting - Parkinson Disease Clinical Trials

Effects of Land and Water Physiotherapy on Motor Function in Parkinson's Disease

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

Parkinson's disease patients have characteristic postural changes in upper limbs, lower limbs and trunk. The presence of kyphosis is observed as the most common postural deformity. The aim of this study is to verify the effect of dry soil therapy and shallow water therapy on muscle function in individuals with Parkinson's disease? Regarding the benefits, is there a difference between the therapies?

NCT ID: NCT05769972 Active, not recruiting - Parkinson Disease Clinical Trials

Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders

CogMusT
Start date: October 13, 2021
Phase: N/A
Study type: Interventional

Mild cognitive impairment associated with movement disorders occurs in up to one third of patients in early stages of the disease, and confers an increased risk of developing dementia. Non-pharmacological interventions to improve cognition have so far been based on computer-based cognitive stimulation and rehabilitation programs. These interventions base their mechanism of action on neuroplasticity and how improvements in cognitive function will generalize to functional improvement. Despite having shown certain indicators of efficacy in previous exploratory studies and clinical trials, cognitive rehabilitation continues to show insufficient evidence and requires further study. To date, there are no previous studies using immersive virtual reality (IVR) to improve cognition. Both IVR and cognitive stimulation are based on the premise that they allow the simulation of ecological environments for rehabilitation than conventional rehabilitation, as well as being more efficient by allowing control of extraneous variables and providing safe spaces for patients. The only PD rehabilitation studies that have been conducted using IVR aimed to improve gait and balance disturbances compared to conventional physiotherapy treatment or non-immersive virtual reality (NIVR). We hypothesize that a cognitive rehabilitation program using IVR or computer-mediated cognitive stimulation could have a greater beneficial effect on the cognitive status of patients with cognitive impairment associated with movement disorders compared to other modalities such as music therapy, delaying the worsening of cognitive functions.

NCT ID: NCT05754086 Active, not recruiting - Parkinson Disease Clinical Trials

A Multidimensional Study on Articulation Deficits in Parkinsons Disease

Start date: September 9, 2021
Phase:
Study type: Observational

Articulatory deficits are present in most speakers with dysarthria, which negatively impacts their speech intelligibility, yet little is known about the relationship between articulatory movement and speech intelligibility. This study will examine the relationship between articulation measures, both acoustic and kinematic, and their relationship to perceptual measures (i.e., speech intelligibility and articulation ratings) in 30 individuals with dysarthria secondary to Parkinson's disease and 30 neurologically healthy adults of the same age. The findings will have implications for behavioral management.

NCT ID: NCT05699460 Active, not recruiting - Parkinson's Disease Clinical Trials

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Start date: September 29, 2022
Phase:
Study type: Observational

The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

NCT ID: NCT05696197 Active, not recruiting - Parkinson Disease Clinical Trials

Learning Potential of Patients With Parkinson's Disease After Two Weeks of Targeted Touchscreen Training

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

Parkinson's disease (PD) is characterized by severe motor and non-motor symptoms, including upper limb dysfunction. Due to the degradation of dopaminergic neurons in the striatum, PD patients experience difficulties with motor learning and more specifically with the consolidation of motor memory. Recent work showed that intensive writing training improved writing skills in PD. Although consolidation effects were present, difficulties with retention were also still apparent. Besides impacting writing, manual dexterity deficits in PD can also affect the use of touchscreens. Researchers from our lab demonstrated that impairments were most pronounced in multi-direction sliding motions, indicating the need for training of these motor skills. Our lab demonstrated the classic difficulties with retention in PD after one session of training of a swipe and slide pattern on a tablet (SSP-task) as single task (ST), although immediate gains were demonstrated. Therefore, in this study the investigators will examine whether a two-week home-based training program of a tablet-based SSP-training program will lead to immediate and consolidated improvements that are retained in time. This program will combine ST and dual task (DT) training to provide variation during the training period, but also to increase the cognitive challenge during learning, thereby stimulation consolidation of learning. The primary aim of this study consists of investigating the learning effects after two weeks of targeted touchscreen training. Secondary, the investigators will examine whether these effects will also be retained after four weeks without practice and whether targeted training results in consolidated improvements, in terms of automaticity and transfer towards an untrained task. Given the objective recording of compliance to the training protocol, the investigators will explore the association between compliance rates and learning effects.

NCT ID: NCT05680961 Active, not recruiting - Parkinson Disease Clinical Trials

Monitoring Movement Disorder Symptoms With a Mobile Medical App on Off-the-shelf Consumer Mobile Devices

Start date: January 19, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate whether New Touch Digital (NTD) NeuroRPM software installed on wearable devices can objectively measure and track symptoms in patients with Parkinson's disease.

NCT ID: NCT05677633 Active, not recruiting - Clinical trials for Parkinson's Disease and Parkinsonism

Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Start date: January 19, 2023
Phase: Phase 1
Study type: Interventional

Investigators will evaluate the safety of a 48 week regimen of Leukine administered as a weight-based dose at 3 ug/kg/ day for 5 days followed by a 2-day holiday. This 48 week long study will extend the prior biomarker evaluations observed in a previous study. Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera panel). Leukapheresis will be performed to collect large numbers of immune cells for biomarker testing and immune phenotyping. Additionally, the investigators will determine whether immune deficits of PD are consistent during baseline data collection, and the potential Leukine-induced motor control and mobility improvements will be determined by UPDRS part I, II, III, and IV scores off treatment and on treatment.

NCT ID: NCT05670782 Active, not recruiting - Parkinson Disease Clinical Trials

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease

Start date: July 19, 2022
Phase: Phase 2
Study type: Interventional

The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.

NCT ID: NCT05622396 Active, not recruiting - Parkinson Disease Clinical Trials

Feasibility of an Adapted Mindfulness Program to Parkinson's Disease

MAdaPARK
Start date: January 16, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.